|Bid Price||-||Offer Price||-|
|Mid Price||GBX 144.40||Day Change||GBX -0.90 (-0.62%)|
|Price Date||22 Sep 2017||Crown Rating|
|Shares Class||Inc.||Yield||0.41 %|
|Total Expense Ratio||0.00||Fund Size||517,026,200.00|
|Launch Date||27/02/1987||Standard Initial Charge (%)||0.00|
|Annual Management Charge (%)||0.65||Sector||IMA UK Equity Income|
|Min Investment (£)||1,000,000.00||Total Expense Ratio (%)||0.00|
|ISIN||GB00BP8XZG68||Min TopUp (£)||5,000.00|
The aim of this Fund is to provide long-term capital growth.
Dani Saurymper joined AXA IM in April 2015 as Portfolio Manager for the AXA Framlington Health funds. Dani has 14 years’ experience. Prior to joining AXA IM in April 2015 as Portfolio Manager, he was a senior equity research analyst covering European Healthcare at Barclays Capital. Dani started his career at Goldman Sachs as a senior pharmaceutical analyst covering European Pharmaceuticals, before moving to Nomura as a sector specialist covering global healthcare. Dani graduated from Leeds University with a BSc in Management Studies and Pharmacology and holds an MSc in International Business from the Manchester School of Management, UMIST.